Month: March 2022

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in the primary efficacy analysis population and by 77% compared to placebo in participants who received treatment within three days of symptom onset Full year and fourth quarter 2021 financial results reported; $591 million in cash and investments expected to be sufficient to fund operations into second half of 2024 WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, reported...

–   Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials –   Eight new programs added to platform since January 2021 bringing total, as of today, to 13 discovery and drug development programs and four enabling technologies –   Ended 2021 very well capitalized with $362 million to execute our strategy to achieve clinically meaningful and sustained behavioral change in mental health patients through the combination of rapid acting interventions, ongoing digital support and biomarker-driven precision...

Achieves Full Year Records for Revenue and Earnings BOSTON HEIGHTS, Ohio, March 30, 2022 (GLOBE NEWSWIRE) — Arhaus, Inc. (NASDAQ: ARHS; “Arhaus” or the “Company”), a rapidly growing lifestyle brand and omni-channel retailer of premium artisan-crafted home furnishings, reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 HighlightsNet revenue increased 46.3% to $238 million Comparable Growth(1) of 40.5% Net and Comprehensive Income of $7 million Adjusted Net Income of $17 million Adjusted EBITDA increased 14.0% to $33 millionFull Year 2021 HighlightsNet revenue increased 57.1% to $797 million Comparable Growth(1) of 51.0% Net and Comprehensive Income of $37 million Adjusted Net Income of $83 million Adjusted EBITDA increased 77.0% to $123 millionFull Year 2022 Outlook...

Fourth quarter and full year revenues of €5.5 billion1 and €19.0 billion1, respectively Full year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.872) Expect to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose a special cash dividend of €2.00 per share, pending approval at the Annual General Meeting Approximately 2.6 billion doses of COMIRNATY®/BNT162b2 delivered to more than 165 countries and regions worldwide in 2021, including more than 1 billion doses to low- and middle-income countries Reiterate BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billion Signed orders for 2022 delivery increased to 2.4 billion COVID-19 vaccine doses Expanded clinical stage oncology pipeline to 16 clinical programs with initiation of nine clinical...

HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) — Vantage Drilling International (“Vantage” or the “Company”) reported a net loss attributable to controlling interest of approximately $23.5 million or $1.79 per diluted share for the three months ended December 31, 2021, as compared to a net loss attributable to controlling interest of $44.9 million or $3.42 per diluted share for the three months ended December 31, 2020. For the year ended December 31, 2021, Vantage reported net loss attributable to controlling interest of approximately $110.1 million or $8.40 per diluted share, as compared to a net loss attributable to controlling interest of $276.7 million or $21.10 per diluted share for the year ended December 31, 2020. As of December 31, 2021, Vantage had approximately $90.6 million in cash, including $17.3 million of restricted...